Lung cancer.. Does early treatment offer a chance to prolong survival?

However, the results apply to a specific group of patients and do not mean the same strategy will benefit all lung cancer patients.

The "DeLLphi-305" trial included 563 patients whose disease had not progressed after receiving initial treatment combining durvalumab with platinum-based chemotherapy and etoposide.

Participants were randomly assigned to two groups: the first received tarlatamab with durvalumab, while the second received durvalumab alone, as part of what is known as maintenance therapy, which aims to maintain disease control after initial treatment.

Here, the word "earlier" does not refer to treating cancer in its early stages, but to adding the drug before new disease progression appears.

The trial results were presented at the European Society for Medical Oncology congress and published simultaneously in the "New England Journal of Medicine." The trial is sponsored by Amgen, with AstraZeneca contributing to its funding and providing durvalumab.

In a pre-planned interim analysis, median overall survival was 21.1 months for those who received tarlatamab and durvalumab, compared to 12.7 months for those who received durvalumab alone.

As for median progression-free survival, it reached 7.4 months with the combination, compared to 1.9 months with the single treatment.

Overall survival measures the time until death from any cause, while progression-free survival measures the time until cancer progression or death occurs. The median here is a measure of the group's results, not a prediction of how long an individual patient will live.

These figures indicate a potentially significant benefit from adding tarlatamab during the maintenance phase, both in prolonging survival and delaying disease progression. However, they do not mean the cancer is eradicated, nor do they alone answer all questions regarding the duration of long-term benefit.

The improvement was accompanied by an increase in treatment-related side effects. Grade 3 or higher adverse events were recorded in 20.9% of patients who received the combination, compared to 10.8% of those who received durvalumab alone.

Cytokine release syndrome also appeared in about half of those receiving the combination. It is an inflammatory response that may occur as a result of immune system activation, and most recorded cases were low-grade, with one grade 3 case recorded.

These results highlight the importance of balancing therapeutic benefit with potential risks, while taking into account the patient's health status, their ability to tolerate treatment, and the requirements for medical monitoring.

The results concern patients with extensive-stage small-cell lung cancer whose disease did not progress after receiving the initial treatment regimen specified in the trial. They cannot be automatically generalized to other types of lung cancer or to patients whose treatment circumstances differ.

Furthermore, the presentation and publication of the results do not necessarily mean this use is approved in all countries, and further follow-up remains important to evaluate the durability of the benefit and long-term safety.

For patients, the decision depends on the extent to which the trial results apply to their condition and balancing the expected benefit with the risks. The broader message is that the stage of disease stability after initial treatment may offer an opportunity to enhance control over it before new progression appears.